NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.
How did NCEL's recent EPS compare to expectations?
The most recent EPS for NewcelX AG is $, expectations of $.
How did NewcelX AG NCEL's revenue perform in the last quarter?
NewcelX AG revenue for the last quarter is $
What is the revenue estimate for NewcelX AG?
According to of Wall street analyst, the revenue estimate of NewcelX AG range from $ to $
What's the earning quality score for NewcelX AG?
NewcelX AG has a earning quality score of B+/56.267757. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does NewcelX AG report earnings?
NewcelX AG next earnings report is expected in 2025-08-14
What are NewcelX AG's expected earnings?
NewcelX AG expected earnings is $, according to wall-street analysts.